2407 — Gaush Meditech Income Statement
0.000.00%
Last trade - 00:00
- HK$2.08bn
- HK$1.91bn
- CNY1.41bn
- 67
- 81
- 11
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,107 | 962 | 1,298 | 1,254 | 1,406 |
Cost of Revenue | |||||
Gross Profit | 463 | 436 | 609 | 625 | 692 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,101 | 810 | 1,353 | 1,486 | 1,108 |
Operating Profit | 5.41 | 152 | -54.4 | -232 | 298 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 2.15 | 149 | -138 | -275 | 248 |
Provision for Income Taxes | |||||
Net Income After Taxes | -38 | 98.5 | -192 | -353 | 173 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -37 | 99.4 | -190 | -350 | 174 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -37 | 99.4 | -190 | -350 | 174 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.25 | 0.672 | -1.18 | -3.34 | 1.17 |
Dividends per Share |